Information Provided By: 
Fly News Breaks for March 15, 2017
AZN, TSRO
Mar 15, 2017 | 08:10 EDT
While Credit Suisse analyst Alethia Young expected TESARO (TSRO) stock weakness into SOLO2 data presented by AstraZeneca (AZN), she thinks the reaction was more overdone than her model would suggest around value of 2L gBRCA market share. The analyst still thinks that TESARO remains a key asset that should have much acquisition interest by global biopharma. Young reiterates an Outperform rating and $198 price target on TESARO's shares.
News For TSRO;AZN From the Last 2 Days
AZN
Apr 16, 2024 | 12:49 EDT
AZN
Apr 16, 2024 | 07:12 EDT
